London, NW10 7EW, United Kingdom
NCT Number: NCT02490358
Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
This study will collect sputum samples from healthy smokers, COPD smokers and COPD ex-smokers to analyse biomarkers of inflammation
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for Healthy Smoking Subjects
- Must have signed an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- Be between 18 and 75 years of age, inclusive, at informed consent.
- Healthy as determined by a physician, based on medical history and physical examination.
- Must have smoked regularly in the 12-month period preceding the screening visit and have a pack history of ≥ 5 pack years (number of pack years = number of cigarettes per day/20 x number of years smoked).
Inclusion criteria
for All COPD Subjects
- Must have signed an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
- Aged between 40 and 75 years of age inclusive, at the time of signing the informed consent.
- COPD diagnosis: Subjects with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli, 2004). Symptoms must be compatible with COPD for at least 1 year prior to screening and post-bronchodilator spirometry readings at screening:
- Post-bronchodilator FEV1/FVC ratio of <0.7
- Post-bronchodilator FEV ≥40 % and ≤80 % of predicted normal values calculated using NHANES reference equations.
Additional Inclusion for Smoking COPD Subjects 1. Must have smoked regularly in the 12-month period preceding the screening visit and have a pack history of ≥ 5 pack years (number of pack years = number of cigarettes per day/20 x number of years smoked).
Exclusion criteria
for Healthy Smoking Subjects Any potential subject who meets any of the following criteria will be excluded from the participating study.
- Upper or lower respiratory tract infection within 4 weeks of the screening visit.
- Positive test for alcohol at screening.
- Taking prescription medication in the 14 days before screening.
- Subjects whose primary consumption of tobacco is via methods other than cigarettes (manufactured or self-rolled). Primary methods of tobacco consumption that are excluded include, but are not limited to pipes, cigars and e-cigarettes.
- Subjects who are unable to produce a total weight of at least 0.1 grams (g) of selected sputum at screening
- Urinary cotinine levels at screening < 30 ng/ml.
- Subject is mentally or legally incapacitated.
- Subject is an employee of the Sponsor or contract research organization (CRO), or a relative of an employee of the Sponsor or CRO.
- Any other reason that the Investigator considers makes the subject unsuitable to participate.
Exclusion criteria
for COPD Subjects Any potential subject who meets any of the following criteria will be excluded from the participating study
- Upper or lower respiratory tract infection within 4 weeks of the screening visit.
- Positive test for alcohol at screening.
- Subjects who are unable to produce a total weight of at least 0.1g of selected sputum at screening.
- Subject is mentally or legally incapacitated.
- Subject is an employee of the Sponsor or contract research organization (CRO), or a relative of an employee of the Sponsor or CRO.
- Any other reason that the Investigator considers makes the subject unsuitable to participate.
- A history of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.
- Taking theophylline in the 28 days before screening
- Change in COPD medication in the 28 days before screening
- Taking oral steroids in the 28 days before screening
Additional Exclusion Criterion for Smoking COPD Subjects
- Subjects whose primary consumption of tobacco is via methods other than cigarettes (manufactured or self-rolled). Primary methods of tobacco consumption that are excluded include, but are not limited to pipes, cigars and e-cigarettes.
- Urinary cotinine levels at screening < 30 ng/ml.
Additional Exclusion Criterion for Ex-Smoking COPD Subjects
- The subject is a smoker (regular or irregular), or has smoked or used nicotine-containing products within the 6 months prior to screening.
Treatment and study plan
Primary outcomes
-
Lipid metabolites in sputum cell homogenate from healthy smokers and smokers and ex-smokers with COPD.
Time frame: 8 months
Sponsors and collaborators
Lead sponsor
Respivert Ltd
Industry
Collaborators
- Babraham Institute Enterprise Limited
Registry information
Official study title
A Sputum Sample Collection Protocol for Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-Smokers
Important dates
- Study start
- 2015
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Jul 3, 2015
- Registry last updated
- Feb 3, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
NCT03927820
Asthma, Bronchial Diseases
Nashville, Tennessee, United States
View Trial DetailsInhaler Trainer Efficacy Study
NCT06461403
Acute Exacerbation of COPD, Asthma
Chicago, Illinois, United States
View Trial DetailsAsthma, Inflammation and G Protein-coupled Receptors (GPCR)
NCT00793676
Asthma, Bronchial Diseases
Colmar, France
View Trial DetailsAn Evaluation of 9MW1911 Injection in Healthy Subjects
NCT05803902
Asthma, Atopic Dermatitis
Beijing, Beijing Municipality, China
View Trial Details